DETECTION OF MALIGNANT CELLS IN MARROW & PBPC FRACTIONS

骨髓中恶性细胞的检测

• 批准号: 2863385
• 负责人: Elizabeth J Shpall
• 金额: $ 13.3万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-09-08 至 2000-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2863385
• 关键词: antitumor antibody; bone marrow; breast neoplasm /cancer diagnosis; breast neoplasms; circulating neoplastic cell; clinical research; cooperative study; diagnosis design /evaluation; female; hematopoietic stem cells; human tissue; immunocytochemistry; keratin; minimal residual disease; monoclonal antibody; neoplasm /cancer epidemiology; neoplasm /cancer immunodiagnosis; polymerase chain reaction; women's health

The specific aims of this project are: 1. To determine the feasibility of assaying the marrow and peripheral blood progenitor cell (PBPC) fractions of breast cancer patients enrolled on S9623 for the presence of malignant cells; 2. To determine the feasibility of quantitating the breast cancer cell content of the marrow and PBPC fractions using immunocytochemistry with anti-breast cancer monoclonal antibodies and reverse transcriptase polymerase chain reaction (RT-PCR) for cytokeratin-19; and, 3. To determine the true incidence of tumor cell contamination of hematopoietic fractions of Stage II/III breast cancer patients with 4-9 axillary lymph nodes. The bulk of our preliminary breast cancer detection data was generated with fresh marrow and PBPC specimens obtained from University of Colorado breast cancer patients. Over the next two years, the current study will determine the feasibility of conducting similar detection studies with patient specimens shipped overnight from the many cooperative group institutions. If this feasibility study is successful, we will be able to determine the incidence of breast cancer contamination in the hematopoietic cell fractions of patients enrolled in the first two years of the study. We will then seek funding for two additional years to continue to assay the hematopoietic cell specimens of patients enrolled on S9623 for the remainder of the study, which is projected to accrue patients for a total of four years. Clinical outcomes, including disease-free survival rates as well as sites and patterns of relapse, will be correlated with the breast cancer detection assay results. Alternatively, if we are unable to successfully assay the specimens shipped from outside institutions, such additional funding will not be sought. The major aspects of the tumor detection assays which the current feasibility pilot will address include: assessment of the quality of the assays performed on specimens shipped overnight; assessment of outside institution compliance; assessment of the true incidence of breast cancer in the hematopoietic cell fractions of Stage II/III 4-9 nod-positive breast cancer patients; and, will compare the sensitivity of the immunohistochemical and molecular assays for breast cancer.

本项目的具体目标是： 1. 确定可行性 测定骨髓和外周血祖细胞 (PBPC) 因存在而注册 S9623 的乳腺癌患者比例 恶性细胞； 2. 确定定量的可行性 骨髓和 PBPC 组分的乳腺癌细胞含量使用 抗乳腺癌单克隆抗体的免疫细胞化学和 逆转录聚合酶链反应 (RT-PCR) 细胞角蛋白-19； 3. 确定肿瘤细胞的真实发生率 II/III 期乳腺癌造血部分的污染 腋窝淋巴结有4-9个的患者。 我们生成了大部分初步乳腺癌检测数据 使用从University of University获得的新鲜骨髓和PBPC标本 科罗拉多州乳腺癌患者。 未来两年内，目前 研究将确定进行类似检测的可行性 对从许多医院连夜运来的患者样本进行研究 合作团体机构。如果这项可行性研究成功的话 我们将能够确定乳腺癌的发病率 入组患者的造血细胞部分受到污染 在学习的前两年。 然后我们将为两个项目寻求资金 继续分析造血细胞样本的额外时间 在 S9623 上登记参加剩余研究的患者人数，即 预计总共四年将吸引患者。 临床 结果，包括无病生存率以及地点和 复发模式将与乳腺癌检测相关 化验结果。 或者，如果我们无法成功检测 从外部机构运送的标本，例如额外的资金 不会被寻求。肿瘤检测分析的主要方面 目前的可行性试点将解决的问题包括： 对隔夜运送的样本进行的检测的质量； 外部机构合规性评估；真实评价 阶段造血细胞部分中乳腺癌的发病率 II/III 4-9 淋巴结阳性乳腺癌患者；并且，将比较 乳腺免疫组织化学和分子检测的敏感性 癌症。